Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech is currently focused on developing Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa), which have shown potential to treat various cancers, viral diseases, and immune-deficiency disorders. The company's recent Q4 2025 results showed a net loss of $4.2 million, but with multiple shots on goal in collaboration with major cancer research centers in the US and promising key clinical data expected in Q1 and Q3 2027, the company's current valuation appears attractive. However, risks to be aware of include the changing macroeconomic factors and competition in the biotech industry.

Bears say

AIM ImmunoTech is a pharmaceutical company that is facing financial struggles as it has minimal revenue and a history of net losses. With only $6 million in cash and $4 million in debt in Q1, the company has turned to selling stock in order to raise funds. Although it has a promising focus on pancreatic cancer treatment, the uncertainty of clinical trials and limited financial resources make this stock a risky investment.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Sep 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.